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coronary bypass. Bubble oxygenators were used exclusively
in their study. They have noted that “there is no evidence
that membrane oxygenators improve cognitive outcome,
despite their ability to reduce microembolic events.”
It has been clearly shown that cognitive outcomes of
patients are strongly associated with the number of emboli
that were delivered during cardiac surgery.2-5 Stump and
associates2 have discovered that patients with neurologic
deficit had twice the number of emboli as those without
deficit in a study of 167 patients. If the number of emboli
was greater than 100, then the patients had significant
neurologic deficit (p 5 0.028). Pugsley and coworkers4
had similar results in a study of 94 patients. When the
number of microemboli was less than 200, five of 58
patients (8.6%) demonstrated a neuropsychologic deficit
at 8 weeks; microemboli count between 201 and 500, three
of 13 patients (23%); microemboli count between 501 and
1000, five of 16 patients (31%); and microemboli count
greater than 1000, three of seven patients (43%).
Blauth and associates6 have discovered that retinal
microembolism and neuropsychologic deficit after CPB
were more common with a bubble oxygenator than with a
membrane oxygenator in a study of 40 patients. All 23
patients (100%) in the bubble oxygenator group had
retinal embolism compared with eight of 17 patients
(47%) in the membrane oxygenator group (p , 0.001).
However, the difference in neuropsychologic deficits was
not statistically significant (p 5 0.11). In a larger study,
Blauth and associates7 have shown that 30 patients
(100%) in the bubble oxygenator group had retinal per-
fusion defects compared with 15 of 34 patients in the
membrane group (p , 0.001).
Several other investigators have documented that the
use of membrane oxygenation causes significantly less
microembolism than the use of bubble oxygenation during
normothermic or hypothermic CPB.8-11 We are surprised
that the use of bubble oxygenators is still dictated by some
institutions.
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Reply to the Editor:
We thank U¨ndar and associates for their interest,
However, we still see no evidence that membrane oxygen-
ators improve cognitive outcome. Of the eleven refer-
ences cited, only the preliminary report by Blauth and
associates1 compared bubble and membrane oxygenators
with regard to postoperative cognitive function. This study
revealed a small, nonsignificant difference in favor of the
membrane oxygenator. The number of patients with post-
operative neuropsychologic impairment was 17 of 22
(77%) in the bubble group and eight of 12 (67%) in the
membrane group (p 5 0.50, x2 done by us). The mean
number of neuropsychologic tests (n 5 10) showing
postoperative deterioration was 1.24 in the bubble group
and 0.91 in the membrane group (p , 0.11, Mann-
Whitney U test, reported by Blauth’s group).
We agree with U¨ndar and associates that cerebral
emboli play a role in postoperative neuropsychologic
dysfunction and that the number of microemboli during
cardiopulmonary bypass is less with membrane than with
bubble oxygenators. Whether this difference would persist
with a 20 mm in-line arterial filter (used in our study) is
not known.
Our practice is to use bubble oxygenators for uncom-
plicated cases and membrane oxygenators for complex
cases. This decision was taken by the cardiac surgeons of
the Royal Victoria Hospital. It was not dictated by hospi-
tal administrators. We think that this approach makes
optimal use of available resources. We believe that the
systematic use of alternative, more expensive equipment
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in the absence of demonstrated improvement in outcome
should be avoided.
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Pulmonary artery banding in Eisenmenger
complex
To the Editor:
The news article titled “Batista Strikes Again to Tackle
Eisenmenger Complex,” published in the May 1997 issue
of The Lancet, has prompted us to review the strategies for
surgical management of patients with Eisenmenger syn-
drome. As a primary step in the treatment of patients with
Eisenmenger complex, Batista1 proposes pulmonary ar-
tery (PA) banding to dilate the pulmonary vascular bed by
reducing PA oxygen saturation (Sao2). Later, when PA
and systemic pressures and arterial blood Sao2 return to
normal values, debanding of the PA and correction of
congenital heart defects are indicated.1 This news brings
to mind an article by Wagenvoort, Wagenvoort, and
Draulans-Noe¨,2 in which the authors compared the mor-
phologic changes in lung biopsy specimens of patients
with congenital heart disease with a shunt and pulmonary
hypertension before and after banding of the PA. These
investigators reported that medial hypertrophy regressed
after PA banding, and in plexogenic pulmonary arteriopa-
thy, the earlier lesions, particularly cellular intimal prolif-
eration, also regressed.
Although lung and heart-lung transplantation are the
only definitive treatments for most adults with Eisen-
menger syndrome, Hopkins and associates3, 4 report that
the natural survival of these patients is better than survival
achieved with transplantation. In this regard, they have
tried to identify means other than transplantation to
improve their quality of life.
Because increased flow is an important pathogenic
element in producing pulmonary hypertension, Dammann
and colleagues5 first performed PA banding to reduce
pulmonary blood flow and PA hypertension and thereby
therapeutically improve congestive heart failure. Serial
biopsy specimens provided good evidence that PA band-
ing was following by regression of the hypertensive
changes in the lung vasculature.5 Batista and associates1
postulate that high PA Sao2, rather than hyperflow, is the
main cause of PA vasoconstriction and PA vascular
resistance. A review6 of the experimental data concerning
the effect of hypoxia on the pulmonary circulation does
not support that hypothesis. Interestingly, in isolated pig
lungs, Sylvester and associates7 observed that reduction of
the alveolar oxygen tension to a level of 50 to 30 mm Hg
led to hypoxic pulmonary vasodilation.
Goldblatt and coworkers8 presume that, in the presence
of a right-to-left shunt, PA banding would increase cardiac
embarrassment, both physiologically and hemodynami-
cally. With a right-to-left shunt, the PA pressure is still
increased, but the pulmonary blood flow is not.8 It is
important to decide how much the PA pressure can be
reduced without compromising the heart’s ability to per-
fuse a highly resistant pulmonary arteriolar bed in Eisen-
menger complex.8 In the course of PA banding, systemic
Sao2 was reduced from 97% to 60% or 75% and pulmo-
nary Sao2 from 87% to about 20%
1 in patients with
right-to-left shunt without compromising the heart (no
respiratory acidosis developed, per a personal communi-
cation with Dr. Randas Batista).
Brammell and colleagues9 suggest that if the pulmonary
vascular bed is reactive, PA banding is not contraindicated
in Wood’s definition of Eisenmenger syndrome. To avoid
a catastrophic outcome, before operating, one can evalu-
ate the reactivity of the pulmonary vascular bed to PA
banding by partially occluding the PA with a balloon-
tipped catheter during preoperative catheterization.
What options remain when lung or heart-lung trans-
plantation is not possible or even advisable,3, 4 especially
for patients from a poor socioeconomic condition who
have pulmonary vasculature changes of Heath-Edwards
grade IV-VI? The choices may be PA banding, with all
supportive measures, or death.
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